MedTrace Logo

A Study to Assess the Long-term Safety of QVA149

NCT01120717 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 339

Last updated 2013-01-31

Study results available
· View outcomes & findings →

Summary

The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

DRUG

QVA149

capsules for inhalation, delivered by an SDDPI

DRUG

Placebo

capsules for inhalation, delivered by an SDDPI

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Canada
  • France
  • Hungary
  • India
  • Latvia
  • Lithuania
  • Romania
  • South Africa
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01120717 on ClinicalTrials.gov